A Non-exclusive Technology Transfer Contract
JW Bioscience, a subsidiary of JW Life Science, announced on Sept. 14 that it has signed a non-exclusive technology licensing-out contract on multiple biomarker CFB and CA19-9 with Swedish diagnostic company Immunovia AB.
The original patented technology is a diagnostic technology that can detect pancreatic cancer early by simultaneously utilizing a biomarker (CFB) which mainly responds to early pancreatic cancer patients, and another (CA19-9) which mainly triggers responses from late pancreatic cancer patients.
JW Bioscience holds the patent in Korea, the United States, 21 European countries, China and Japan. JW Holdings, the holding company of JW Group, registered the patent right in Japan, China, Europe, and the United States between 2018 and 2020.
Under this contract, Immunovia has secured the right to commercialize CFB and CA19-9 globally. JW Bioscience is expected to gain a footing in the global in vitro diagnosis market with the licensing-out contract with Immunovia.